Biocon Ltd, Asia's premier biotechnology company, introduces an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of the innovator product commercialized by Gilead Sciences in the US.
Researchers have developed a cost-effective one-step test that can screen, detect and confirm hepatitis C virus (HCV) infections from blood or urine samples. Current blood-based HCV testing requires two steps and can be expensive, inconvenient and is not widely available or affordable globally.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
